Clinical Trial Update: First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated gefitinib as first-line therapy for patients with EGFR-mutant non-small cell lung cancer (adenocarcinoma); the study results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary Cancer | Phase 2 | Status: COMPLETED | Results posted: 2010-06-04